Prognostic impact of the number and total tumor burden of secondary cerebral lesions in patients with resected brain metastases of non–small cell lung cancers
Sidonie Sauvageot,Caroline Mollevi,Quentin D. Thomas,Marie Charissoux,Amélie Darlix,Valérie Rigau,Luc Bauchet,Xavier Quantin,Jean Louis Pujol,Benoit Roch,Julien Boetto
DOI: https://doi.org/10.3171/2023.11.jns231923
IF: 5.408
2024-01-01
Journal of Neurosurgery
Abstract:OBJECTIVE Systemic therapeutic advancements have improved the prognosis of cancer patients, leading to surgery more frequently being carried out for patients with multiple brain metastases (BM). The underlying evidence for the strategy is currently lacking. This study aimed to evaluate the prognostic significance of the number of BM and total tumor burden (TTB) on the overall survival (OS) of patients with resected BM of non–small cell lung cancer (NSCLC) in a modern series. METHODS In this monocentric retrospective series, patients who underwent resection of BM of NSCLC between 2015 and 2021 were included. Demographic, clinical, and histological parameters were collected, and formal radiological volumetric analyses were performed. Prognostic biomarkers for cerebral progression-free survival (C-PFS) and OS were analyzed with univariate and multivariate Cox proportional hazards analysis. RESULTS One hundred eighty-four patients were included in the study. Among these, 108 patients (58.7%) presented with a single brain metastasis, 36 patients (19.6%) with 2 BM, 22 patients (11.9%) with 3 BM, and 18 patients (9.8%) with more than 3 BM (maximum 15 BM). The mean ± SD (range) preoperative tumor burden was 23.1 ± 25.3 (1.1–145.3) cm 3 . The mean residual tumor burden after surgery was 0.3 ± 0.8 (0.0–6.3) cm 3 . By the time of the analysis, 128 patients (69.6%) had died. The median follow-up duration was 49.0 months (95% CI 39.6–63.6). The median OS was 19.2 months (95% CI 13.2–24.0), and the survival rates at 6 months, 1 year, and 2 years were 76% (95% CI 69%–82%), 61% (95% CI 53%–67%), and 43% (95% CI 35%–50%), respectively. The median C-PFS was 8.4 months (95% CI 7.2–12.0). In the Cox multivariate regression model, younger age (< 65 years), single brain metastasis, adjuvant brain radiation therapy, adjuvant use of targeted therapy, and TTB < 7 cm 3 were all independent predictors of longer OS. CONCLUSIONS In this era of modern systemic treatments for cancer, the number of BM and total cerebral tumor burden remain significant prognostic factors of OS. However, resection should be considered as an option even in those patients with multiple BM in order to enhance patient clinical status, enable further local and systemic treatment delivery, and improve their survival and quality of life.
surgery,clinical neurology